Amprenavir (APV), fosamprenavir (FPV), lopinavir (LPV), ritonavir (RTV) and efavirenz (EFV) are to varying degrees substrates, inducers and inhibitors of CYP3A4. Coadministration of these drugs might result in complex pharmacokinetic drug-drug interactions.
Methods
Two prospective, open-label, non-randomized studies evaluated APV and LPV steady-state pharmacokinetics in HIV-infected patients on APV 750 mg twice daily + LPV/RTV 533/133 mg twice daily with EFV (n=7) or without EFV (n=12) + background nucleosides (Study 1) and after switching FPV 1,400 mg twice daily for APV (n=10) (Study 2).
Results
In Study 1 EFV and non-EFV groups did not differ in APV minimum plasma concentration (Cmin; 1.10 versus 1.06μg/ml, P=0.89), area under the concentration-time curve (AUC; 17.46 versus 24.34μg•h/ml, P=0.22) or maximum concentration (Cmax; 2.61 versus 4.33 μg/ml, P=0.08); for LPV there was no difference in Cmin (median: 3.66 versus 6.18μg/ml, P=0.20), AUC (81.84 versus 93.75 μg•h/ml, P=0.37) or Cmax (10.36 versus 10.93 μg/ml, P=0.61). In Study 2, after switching from APV to FPV, APV Cmin increased by 58% (0.83 versus 1.30 μg/ml, P=0.0001), AUC by 76% (19.41 versus 34.24 μg•h/ml, P=0.0001), and Cmax by 75% (3.50 versus 6.14, P=0.001). Compared with historical controls, LPV and RTV pharmacokinetics were not changed. All treatment regimens were well tolerated. Seven of eight completers (88%) maintained HIV-1 RNA <400 copies/ml 12 weeks after the switch (1 lost to follow up).
Conclusions
EFV did not appear to significantly alter APV and LPV pharmacokinetic parameters in HIV-infected patients taking APV 750 mg twice daily + LPV 533/133 mg twice daily. Switching FPV 1,400 mg twice daily for APV 750 mg twice daily resulted in an increase in APV Cmin, AUC, and Cmax without changing LPV or RTV pharmacokinetics or overall tolerability.
References
1.
PaulsenD., LiaoQ., FuscoG.Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.AIDS Res Hum Retroviruses2002; 18: 1011–1019.
2.
De LucaA., BaldiniF., CingolaniA.Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.J Acquir Immune Defic Syndr2004; 35: 359–366.
3.
RaguinG., ChêneG., Morand-JoubertL.Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.Antivir Ther2004; 9: 615–625.
4.
WireM.B., SheltonM.J., StudenbergS.Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug.Clin Pharmacokinet2006; 45: 137–168.
5.
Wynn VezinaH., BrundageR., BushmanL., FletcherC.Pharmacologic management of the drug-drug interaction between lopinavir/ritonavir and amprenavir.11th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2004, San Francisco, CA, USA. Poster 609.
6.
MeynardJ.L., PoirierJ.M., Guiard-SchmidJ.B.Impact of ABT 378/r on the amprenavir plasma concentrations in HIV-experienced patients treated by the association of APV - ABT 378/r.41st Interscience Conference on Antimicrobial Agents and Chemotherapy. 16–19 December 2001, Chicago, IL, USA. Abstract 1736.
7.
PeytavinG., LamotteC., DuvalX.Amprenavir plasma concentrations are dramatically decreased by association with ABT/378/r in HIV-infected patients. 2nd International Workshop on Clinical Pharmacology of HIV Therapy. 2–4 April 2001, Noordwijk, the Netherlands. Abstract 1.14.
8.
SolasC., QuinsonA.M., CouprieC.Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. 9th Conference on Retroviruses and Opportunistic Infections. 24–28 February 2002. Seattle, WA, USA. Abstract 440-W.
9.
MaussS., ScholtenS., WolfE.A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.HIV Med2004; 5: 15–17.
10.
TaburetA.M., RaguinG., Le TiecC.Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.Clin Pharmacol Ther2004; 75: 310–323.
11.
BertzR., FoitC., AshbrennerE.Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy subjects. 42nd Interscience conference on Antimicrobial Agents and Chemotherapy. 27–30 September 2002, San Diego, CA, USA. Abstract A-1823.
12.
TurnerM.L., Reed-WalkerK., KingJ.R., AcostaE.P.Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.J Chromatog B Analyt Technol Biomed Lif Sci2003; 784: 331–341.
13.
VeldkampA.I., van HeeswijkR.P.G., MeenhorstP.L.Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor in human plasma using isocratic reverse-phase high-performance liquid chromatography with ultraviolet detection.J Chromatog B Biomed Appl1999; 734: 55–61.
14.
DeJesusE., LamarcaA., SensionM.The CONTEXT study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure — 24-week results. 10th Conference on Retroviruses and Opportunistic Infections. 10–14 February 2003, Boston, MA, USA. Abstract/presentation 178.
15.
WireM., NadererO., MastermanA.The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV 10011 and APV 10012). 11th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2004, San Francisco, CA, USA. Abstract 612.
16.
KempfD.J., IsaacsonJ.D., KingM.S.Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.J Virol2001; 75: 7462–7469.
17.
MorseG.D., RosenkranzS., ParaM.F.Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.Antimicrob Agents Chemother2005; 49: 3373–3381.
18.
SaleM., SadlerB.M., SteinD.S.Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Antimicrob Agents Chemother2002; 46: 746–754.
19.
Panel on Antiretroviral Guidelines for Adult and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.Department of Health and Human Services [updated 2006 October 10; cited 2007 August 3]. Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
20.
KashubaA.D., TierneyC., DowneyG.F.Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.AIDS2005; 19: 145–152.
21.
KaplanS.S., HicksC.B.Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.Expert Opin Pharmacother2005; 6: 1573–1585.
